T4	total-participants 324 335	One hundred
T5	eligibility 336 382	hormone-insensitive breast cancer participants
T6	age 389 400	18-40 years
T7	location 468 473	Egypt
T8	total-participants 568 573	Fifty
T9	outcome-Measure 1085 1150	Resumption of menstruation at 12 months after end of chemotherapy
T13	control 643 661	chemotherapy alone
T14	iv-bin-percent 1435 1438	80%
T16	cv-bin-percent 1544 1547	80%
T17	iv-bin-percent 1552 1555	84%
T12	outcome 1328 1357	menstruation resumption rates
T18	outcome 1666 1697	hormonal and ultrasound markers
T15	intervention 0 25	Gonadatrophin suppression
T19	condition 37 72	chemotherapy-induced ovarian damage
T1	total-participants 948 950	50
T2	outcome-Measure 1176 1201	Postchemotherapy hormonal
T3	outcome-Measure 1206 1224	ultrasound changes
